A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors
The eradication of solid tumors by chimeric antigen receptor (CAR) T cells requires dynamic therapies capable of outlasting an immune suppressive tumor microenvironment (TME). However, biological barriers--including rapid exhaustion, poor expansion, and loss of stem-like memory--quickly neutralize these therapies. Because single-technology interventions often introduce unacceptable tradeoffs…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
